OncoMatch/Clinical Trials/NCT06587061
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Is NCT06587061 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies HRS-4642+AG for pancreatic cancer.
Treatment: HRS-4642+AG — To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage RESECTABLE PANCREATIC CANCER (INCLUDING HIGH-RISK RESECTABLE), BORDERLINE RESECTABLE PANCREATIC CANCER (NCCN guidelines)
Excluded: Stage DISTANT METASTATIC
Imaging evaluation met the NCCN guidelines definition of resectable pancreatic cancer (including high-risk resectable) and borderline resectable pancreatic cancer. the presence of distant metastatic lesions diagnosed by imaging [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-tumor therapy
Previously received any anti-tumor therapy
Lab requirements
Blood counts
adequate marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06587061 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage RESECTABLE PANCREATIC CANCER (INCLUDING HIGH-RISK RESECTABLE) or BORDERLINE RESECTABLE PANCREATIC CANCER is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages